PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
14.27%
Revenue growth exceeding 1.5x Medical - Pharmaceuticals median of 1.98%. Joel Greenblatt would verify if operating margins keep pace with this top-line surge.
9.27%
Gross profit growth exceeding 1.5x Medical - Pharmaceuticals median of 2.16%. Joel Greenblatt would check if cost advantages or brand equity drive this surge.
16.77%
EBIT growth of 16.77% while Medical - Pharmaceuticals median is zero. Walter Schloss would see a marginal edge that could be expanded upon.
29.33%
Operating income growth of 29.33% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest advantage that can expand.
31.60%
Net income growth of 31.60% while Medical - Pharmaceuticals median is zero. Walter Schloss might see potential if moderate gains can keep rising.
31.60%
EPS growth of 31.60% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight edge that could compound over time.
31.60%
Diluted EPS growth of 31.60% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight edge that could improve over time.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
77.86%
10Y revenue/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 48.54%. Joel Greenblatt would verify if a unique moat or brand fosters outperformance over a decade.
81.50%
5Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 32.99%. Joel Greenblatt would see if the company’s moat drives rapid mid-term expansion.
44.91%
3Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 17.30%. Joel Greenblatt might see a short-term competitive advantage at play.
-100.00%
Negative 10Y OCF/share CAGR while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
149.69%
Net income/share CAGR of 149.69% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a marginal edge that can grow if the firm invests wisely.
103.51%
5Y net income/share CAGR > 1.5x Medical - Pharmaceuticals median of 11.17%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
27.68%
3Y net income/share CAGR > 1.5x Medical - Pharmaceuticals median of 4.26%. Joel Greenblatt might see a recent surge from market share gains or cost synergy.
198.41%
Equity/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 106.56% over 10 years. Joel Greenblatt would see if a high ROE underlies this compounding advantage.
123.92%
5Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 28.53%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
56.55%
3Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 16.89%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
160.87%
Dividend/share CAGR of 160.87% while Medical - Pharmaceuticals is zero. Walter Schloss sees a minor improvement that could compound if the firm maintains consistent raises.
84.62%
5Y dividend/share CAGR of 84.62% while Medical - Pharmaceuticals is zero. Walter Schloss sees at least some improvement that could compound over time.
33.33%
3Y dividend/share CAGR of 33.33% while Medical - Pharmaceuticals is zero. Walter Schloss sees a slight advantage if the firm is at least inching up payouts.
-48.82%
AR shrinking while Medical - Pharmaceuticals median grows. Seth Klarman sees potential advantage unless it signals declining demand.
7.60%
Inventory growth of 7.60% while Medical - Pharmaceuticals median is zero. Walter Schloss checks if we’re preparing for a sales push or risking overstock.
13.64%
Asset growth of 13.64% while Medical - Pharmaceuticals median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
5.21%
BV/share growth of 5.21% while Medical - Pharmaceuticals is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
63.09%
Debt growth of 63.09% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest difference that matters if interest coverage is tight.
No Data
No Data available this quarter, please select a different quarter.
-44.38%
SG&A decline while Medical - Pharmaceuticals grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.